BindingDB logo
myBDB logout

16 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
28222316 165 Discovery and characterization of novel CYP1B1 inhibitors based on heterocyclic chalcones: Overcoming cisplatin resistance in CYP1B1-overexpressing lines.EBI De Montfort University
28212021 111 Discovery and Development of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole Dimesylate Monohydrate (SUVN-502): A Novel, Potent, Selective and Orally Active Serotonin 6 (5-HTEBI Suven Life Sciences Ltd
28212015 51 Discovery and Preclinical Characterization of 3-((4-(4-Chlorophenyl)-7-fluoroquinoline-3-yl)sulfonyl)benzonitrile, a Novel Non-acetylenic Metabotropic Glutamate Receptor 5 (mGluR5) Negative Allosteric Modulator for Psychiatric Indications.EBI Gedeon Richter Plc
28038328 17 Design, synthesis and biological evaluation of indolin-2-one-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase3 (FLT3).EBI East China University of Science and Technology
28072531 120 Discovery of 2-(((1r,4r)-4-(((4-Chlorophenyl)(phenyl)carbamoyl)oxy)methyl)cyclohexyl)methoxy)acetate (Ralinepag): An Orally Active Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension.EBI Arena Pharmaceuticals
28337332 41 BMS-933043, a Selectivea7 nAChR Partial Agonist for the Treatment of Cognitive Deficits Associated with Schizophrenia.EBI Bristol-Myers Squibb
28337324 14 Discovery of GBT440, an Orally Bioavailable R-State Stabilizer of Sickle Cell Hemoglobin.EBI Global Blood Therapeutics, Inc.
27914363 6 New insights into the SAR and drug combination synergy of 2-(quinolin-4-yloxy)acetamides against Mycobacterium tuberculosis.EBI Pontif£cia Universidade Cat£lica do Rio Grande do Sul
28337320 21 Discovery and Assessment of Atropisomers of ()-Lesinurad.EBI WuXi AppTec
28003141 65 Identification and optimization of a novel series of indoleamine 2,3-dioxygenase inhibitors.EBI Bristol-Myers Squibb Research and Development
28523115 59 Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DPEBI Novartis Institutes for Biomedical Research
28064141 12 Methoxylated 2'-hydroxychalcones as antiparasitic hit compounds.EBI University of Modena and Reggio Emilia
28103022 36 Discovery of a Novel Series of Orally Bioavailable and CNS Penetrant Glucagon-like Peptide-1 Receptor (GLP-1R) Noncompetitive Antagonists Based on a 1,3-Disubstituted-7-aryl-5,5-bis(trifluoromethyl)-5,8-dihydropyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione Core.EBI Vanderbilt University
27992216 62 Discovery of a Highly Potent, Selective, and Metabolically Stable Inhibitor of Receptor-Interacting Protein 1 (RIP1) for the Treatment of Systemic Inflammatory Response Syndrome.EBI National Institute of Biological Sciences
19041240 41 Lead identification to generate 3-cyanoquinoline inhibitors of insulin-like growth factor receptor (IGF-1R) for potential use in cancer treatment.BDB Wyeth Research
17949010 16 Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity.BDB Pfizer